Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
42.3M
-
Number of holders
-
192
-
Total 13F shares, excl. options
-
40.3M
-
Shares change
-
-3.05M
-
Total reported value, excl. options
-
$2.23B
-
Value change
-
-$65.4M
-
Put/Call ratio
-
4.31
-
Number of buys
-
106
-
Number of sells
-
-77
-
Price
-
$55.37
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) as of Q4 2024
223 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) has 192 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.3M shares
of 42.3M outstanding shares and own 95.23% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (3.54M shares), RTW INVESTMENTS, LP (3.24M shares), Paradigm Biocapital Advisors LP (2.53M shares), JENNISON ASSOCIATES LLC (2.5M shares), TANG CAPITAL MANAGEMENT LLC (2.25M shares), VANGUARD GROUP INC (2.12M shares), MORGAN STANLEY (1.97M shares), TORONTO DOMINION BANK (1.91M shares), Frazier Life Sciences Management, L.P. (1.59M shares), and LORD, ABBETT & CO. LLC (1.28M shares).
This table shows the top 192 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.